Polymorphisms in the human paraoxonase (PON1) promoter

Pharmacogenetics

Volumn 11, Issue 1, 2001, Pages 77-84

  Brophy, V H ^a   Hastings, M D ^a   Clendenning, J B ^a   Richter, R J ^a   Jarvik, G P ^a   Furlong, C E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Atherosclerosis; Gene expression; Organophosphorus insectisides; PON1; Promoter polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CELL SPECIFICITY; DNA DETERMINATION; DNA POLYMORPHISM; DNA SEQUENCE; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY; LIVER; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; YEAST ARTIFICIAL CHROMOSOME;

ARYLDIALKYLPHOSPHATASE; CELL LINE; ESTERASES; GENE EXPRESSION REGULATION; HAPLOTYPES; HUMANS; MUTAGENESIS, SITE-DIRECTED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035133226     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200102000-00009     Document Type: Article

References (50)

1. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase
2. Chapter II
3. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
4. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype
5. CCR5 promoter polymorphisms, CCR559029A and CCR559353C, are under represented in HIV-1-infected long-term non-progressors
6. Structural organization of the human PON1 gene
7. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
8. A pitfall of using a second plasmid to determine transfection efficiency
9. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response
10. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase
11. Genetically determined susceptibility to organophosphorus insecticides and nerve agents: Developing a mouse model for the human PON1 polymorphism
12. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
13. A human chromosome 7 yeast artificial chromosome (YAC) resource: Construction, characterization, and screening
14. Stimulation of transcription in vitro by binding sites for nuclear factor I
15. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence
16. Expanding the TRANSFAC database towards an expert system of regulatory molecular mechanisms
17. CLUSTAL V: Improved software for multiple sequence alignment
18. A 1O-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli
19. The molecular basis of the human serum paraoxonase activity polymorphism
20. Smoking is associated with reduced serum paraoxonase activity, concentration in patients with coronary artery disease
21. 55 genotype
22. Human hepatocellular carcinoma cell lines secrete the major plasma proteins, hepatitis B surface antigen
23. An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism
24. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
25. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism
26. Serum paraoxonase status: A major factor in determining resistance to organophosphates
27. Paraoxonase protects against chlorpyrifos toxicity in mice
28. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphates
29. Low A-esterase activity in serum of patients with fish-eye disease
30. Absence of 'A'-esterase activity in the serum of a patient with Tangier disease
31. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus
32. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
33. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation
34. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
35. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in noninsulin dependent diabetes mellitus
36. Genetic acceleration of AIDS progression by a promoter variant of CCR5
37. A simple salting out procedure for extracting DNA from human nucleated cells
38. Adenovirus DNA replication in vitro: Identification of a host factor that stimulates synthesis of the preterminal protein-dCMP complex
39. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio
40. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols
41. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family
42. MatInd and MatInspector: New fast and versatile tools for detection of consensus matches in nucleotide sequence data
43. Determination of paraoxonase (PON1) status requires more than genotyping
44. A family of human CCAAT-box-binding proteins active in transcription and DNA replication: Cloning and expression of multiple cDNAs
45. TESS: Transcription Element Search Software on the WWW
46. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model
47. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
48. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression
49. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice
50. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein